Intellectual Property India Publishes Patent Application for 'New E3 Ubiquitin Ligase Ligand, Protein Degradation Agent And Use Thereof' Filed by Gluetacs Therapeutics (SHANGHAI) Co. Ltd.

MUMBAI, India, Oct. 31 -- Intellectual Property India has published a patent application (202517094011 A) filed by Gluetacs Therapeutics (SHANGHAI) Co. Ltd., Shanghai, on Sept. 30, for 'new e3 ubiquitin ligase ligand, protein degradation agent and use thereof.'

Inventor(s) include Yang, Xiaobao; Sun, Renhong; Li, Yan; and Zhao, Baoyin.

The application for the patent was published on Oct. 31, under issue no. 44/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to compounds of formula (I) and formula (II), or salts, enantiomers, stereoisomers, solvates, isotope-enriched analogs, prodrugs or polymorphs thereof; and the use thereof. The present disclosure also relates to a pharmaceutical composition comprising the compound of formula (I), or a salt, a enantiomer, a stereoisomer, a solvate, an isotope-enriched analog, a prodrug or a polymorph thereof as an active ingredient; and the use thereof."

The patent application was internationally filed on Mar. 11, 2024, under International application No.PCT/CN2024/080926.

Disclaimer: Curated by HT Syndication.